#New York #Class Action #Fractyl Health #GUTS

Fractyl Health Investors File Class Action

In a significant development for Fractyl Health, Inc. (NASDAQ: GUTS), investors are mobilizing in response to a securities class action lawsuit that has emerged amidst serious allegations regarding the company's reporting of clinical data. The suit represents shareholders who invested between January 13, 2025, and January 29, 2026, reflecting widespread dissatisfaction over the handling of essential trial outcomes.

The Set-Up: A Promising Start

In September 2025, Fractyl Health proudly announced its clinical data from the REM-1 Midpoint Cohort. It indicated that patients treated with Revita, a treatment device aimed at aiding weight loss through innovative approaches, lost an additional 2.5% of total body weight after discontinuing GLP-1 drugs. This announcement was met with enthusiasm, and the company positioned itself to capitalize on these results by launching a 60 million shares offering, priced at $1.00 a share.

The Downfall: Reality Sets In

However, only a few months later, investors were faced with starkly contrasting data; the six-month results showed Revita-treated individuals actually regained 4.5% of their weight, raising serious questions about the efficacy of the treatment. The abrupt shift in data led GUTS shares to plummet, closing at $0.46 after significant losses over the month. The initial excitement had quickly turned into disappointment, with the cumulative decline from the reference price reflecting a staggering 74.86% drop.

The Lawsuit Claims

The class action lawsuit claims that Fractyl Health misled investors by presenting the efficacy of the Revita treatment in a favorable light while failing to disclose critical operational issues affecting study integrity. The allegations point to problems at one of the study sites, noted for its